About the Oncotype DX AR-V7 Nucleus Detect test

Why Order the Oncotype DX AR-V7 Nucleus Detect Test?


Quickly and confidently determine if your mCRPC patient is likely to benefit from an AR-targeted therapy.

The first and only test of its kind to identify patients who will NOT respond to AR-targeted therapies

Finding the most effective treatment for your patients with metastatic castration-resistant prostate cancer (mCRPC) can be a challenge. The Oncotype DX AR-V7 Nucleus Detect test helps you quickly and confidently determine the next step.

Accurately identify patients resistant to targeted therapies

Not all mCRPC patients respond to androgen receptor (AR)-targeted therapies, like abiraterone and enzalutamide.1 When AR-targeted therapy fails, acquired resistance could be the cause. The only predictive and prognostic test for men with mCRPC, the AR-V7 Nucleus Detect test:

  • Accurately identifies patients who will not benefit from AR-targeted therapies.
  • Is predictive of improved overall survival with taxanes versus AR-targeted therapies.
  • Provides easy-to-interpret results (a positive or negative result).


mCRPC Image


The AR-V7 Nucleus Detect test provides unparalleled specificity by detecting AR-V7 proteins in the nucleus of circulating tumor cells (not cytoplasmic AR-V7 proteins). Find out more about nuclear detection.

Order the test each time the risk of resistance increases

Over time, tumors can adapt (and become resistant) to AR-targeted treatments. The percentage of patients who are nuclear AR-V7+ (an absolute indicator that a patient will not respond to AR-targeted therapies) increases with each exposure to AR-targeted therapies.2

  • Roughly 1 in 5 patients (18%) are nuclear AR-V7+ after receiving abiraterone or enzalutamide.
  • Roughly 1 in 3 patients (31%) are nuclear AR-V7+ after receiving two rounds of AR-targeted therapy.

The percentage of mCRPC patients with the AR splice variant (AR-V7+) increased with continued exposure to AR-targeted therapies2

AR Resistance Graph
Cross-sectional cohort study. Blood samples were collected from 161 patients with mCRPC and tested for the presence of AR-V7.

No intrusive procedures required

A liquid biopsy, the AR-V7 Nucleus Detect test analyzes circulating tumor cells in the patient’s blood. The sample is obtained through a simple blood draw and sent to our clinical laboratory. No intrusive or complicated procedures are required. The results are reported to the ordering physician confirming the patient as either AR-V7+ or AR-V7-. Learn how to order and use the AR-V7 Nucleus Detect test.


1. Antonarakis et al. N Engl J Med. 2014.
2. Scher et al. JAMA Oncol. 2016.

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.